TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07542808: An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal Cell Product StromaForte Compared With Hyaluronic Acid for the Treatment of Kne

Sponsor: Cellcolabs Clinical SPV Limited · Phase: PHASE2/PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 140 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$13,468,800

Rescue Site Savings

+$8,880,990

Unlock Full NCT07542808 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07542808 Rescue Dossier →